MX2021009829A - Biomarcadores salivales de lesion cerebral. - Google Patents

Biomarcadores salivales de lesion cerebral.

Info

Publication number
MX2021009829A
MX2021009829A MX2021009829A MX2021009829A MX2021009829A MX 2021009829 A MX2021009829 A MX 2021009829A MX 2021009829 A MX2021009829 A MX 2021009829A MX 2021009829 A MX2021009829 A MX 2021009829A MX 2021009829 A MX2021009829 A MX 2021009829A
Authority
MX
Mexico
Prior art keywords
brain injury
salivary biomarkers
tbi
diagnosing
predicting
Prior art date
Application number
MX2021009829A
Other languages
English (en)
Inventor
Antonio Belli
Pietro Valentina Di
Original Assignee
Marker Diagnostics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marker Diagnostics Uk Ltd filed Critical Marker Diagnostics Uk Ltd
Publication of MX2021009829A publication Critical patent/MX2021009829A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los métodos de diagnóstico, monitoreo, tratamiento y predicción del curso de la lesión cerebral traumática (LCT), que incluye la lesión cerebral traumática leve (LCTL), incluyen determinar un nivel de al menos un biomarcador de ARN (por ejemplo, miARN) en una muestra de saliva de un sujeto. También se describen elementos sensores, sistemas de detección, composiciones y estuches para diagnosticar, monitorear, tratar y predecir el curso de la LCT.
MX2021009829A 2019-02-14 2020-02-14 Biomarcadores salivales de lesion cerebral. MX2021009829A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962805761P 2019-02-14 2019-02-14
US201962884104P 2019-08-07 2019-08-07
PCT/IB2020/051273 WO2020165863A2 (en) 2019-02-14 2020-02-14 Salivary biomarkers of brain injury

Publications (1)

Publication Number Publication Date
MX2021009829A true MX2021009829A (es) 2021-12-10

Family

ID=69740439

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009829A MX2021009829A (es) 2019-02-14 2020-02-14 Biomarcadores salivales de lesion cerebral.

Country Status (17)

Country Link
US (1) US20220380850A1 (es)
EP (1) EP3924518A2 (es)
JP (1) JP2022520427A (es)
KR (1) KR20220002867A (es)
AU (1) AU2020220963A1 (es)
BR (1) BR112021015845A2 (es)
CA (1) CA3129034A1 (es)
CL (1) CL2021002121A1 (es)
CO (1) CO2021011964A2 (es)
CR (1) CR20210466A (es)
IL (1) IL285446A (es)
MX (1) MX2021009829A (es)
PE (1) PE20220877A1 (es)
SG (1) SG11202108664RA (es)
TW (1) TW202045734A (es)
WO (1) WO2020165863A2 (es)
ZA (1) ZA202106673B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4314341A1 (en) * 2021-04-02 2024-02-07 Marker Holdings AG Biomarkers of musculoskeletal injury

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5909447B2 (ja) * 2009-09-14 2016-04-26 バンヤン・バイオマーカーズ・インコーポレーテッド ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー
WO2015134551A1 (en) * 2014-03-03 2015-09-11 Banyan Biomarkers, Inc. Micro rna markers for diagnosis of a neurological condition
GB201603967D0 (en) 2016-03-08 2016-04-20 Univ Birmingham Biomarkers of traumatic brain injury
KR102621064B1 (ko) * 2017-03-23 2024-01-03 콰드런트 바이오사이언시즈 인코포레이티드 외상성 뇌 손상 및 뇌진탕 증상의 분석 및 예측

Also Published As

Publication number Publication date
EP3924518A2 (en) 2021-12-22
IL285446A (en) 2021-09-30
BR112021015845A2 (pt) 2021-10-05
TW202045734A (zh) 2020-12-16
SG11202108664RA (en) 2021-09-29
WO2020165863A2 (en) 2020-08-20
CA3129034A1 (en) 2020-08-20
PE20220877A1 (es) 2022-05-27
AU2020220963A1 (en) 2021-09-02
ZA202106673B (en) 2024-02-28
WO2020165863A3 (en) 2020-09-24
CL2021002121A1 (es) 2022-03-25
CO2021011964A2 (es) 2021-12-10
CR20210466A (es) 2022-02-08
US20220380850A1 (en) 2022-12-01
JP2022520427A (ja) 2022-03-30
KR20220002867A (ko) 2022-01-07

Similar Documents

Publication Publication Date Title
EP4257705A3 (en) Biomarkers of traumatic brain injury
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
WO2014201516A3 (en) Biomarker identification
GB2484764B (en) Normalizing chromosomes for the determination and verification of common and rare chromosomal aneuploidies
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
WO2015164431A3 (en) Methods, processes, devices and kits for the measurement of post traumatic stress disorder microrna markers
EP3907509A3 (en) Diagnosis of early stage pancreatic cancer
MX2019008911A (es) Metodos, matrices y usos de estos.
BR112018073214A2 (pt) métodos para a previsão do risco de recorrência da fibrilação atrial, para o diagnóstico de fibrilação atrial em um indivíduo, para o monitoramento de uma terapia e para a classificação da fibrilação e utilizações do biomarcador
BRPI0419002A (pt) método para detectar e para diferenciação entre adenoma colorretal e/ou carcinoma colorretal, método para monitoramento do curso de adenoma colorretal, uso de transtirretina como biomarcador, sistema de teste, arranjo compreendendo moléculas de detecção
ZA202106673B (en) Salivary biomarkers of brain injury
GB2494580A (en) Method for diagnosing lung cancer
MX2019008005A (es) Metodos y composiciones para diagnosticar preeclampsia.
WO2020115270A3 (en) Biomarker for detecting zearalenone effect
EA202192186A1 (ru) Слюнные биомаркеры травмы головного мозга
TR201814812A2 (tr) Performans ölçme prosesi̇
WO2019053117A8 (en) Pct and pro-adm as markers for monitoring antibiotic treatment
WO2018208749A8 (en) PROSTATE CANCER GENE PROFILES AND THEIR METHODS OF USE
NO20080510L (no) Anvendelse av endoplasminfragment og derivater derav som biomarkor for colorektal adenom og/eller karsinom, samt testsystem og fremgangsmate for deteksjon
WO2021138273A3 (en) Autoantibodies as biomarkers for autoimmune polyglandular syndrome type 1
AR118109A1 (es) Composición, equipo médico, elemento sensor, sistema y método de detección de biomarcadores para su uso en lesiones cerebrales traumáticas
WO2020127499A3 (en) Mirnas as biomarkers for parkinson's syndrome
WO2017156154A9 (en) Compositions for characterizing development of esophageal adenocarcinoma in patients and methods of use thereof
WO2023283476A3 (en) Circulating microrna signatures for pancreatic cancer
EP4024049A4 (en) BIOMARKER COMPOSITION FOR DIAGNOSING MILD COGNITIVE IMPAIRMENT USING NASAL FLUID SAMPLE AND METHOD FOR DIAGNOSING MILD COGNITIVE IMPAIRMENT USING SAME